Health

Results: 37-48 of 5318

PR Newswire associated0

Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation

Implantica presents the first quarter 2025 on May 9 at 15:00 CEST

HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion

Prothena to Report First Quarter 2025 Financial Results on May 8

AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN

PCI Pharma Services enhances US manufacturing of prefilled syringes & cartridges through acquisition of Ajinomoto Althea.

Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges

Crown Bioscience and NEXT Oncology Cement Partnership Extension

Headspace's Finding Your Best Sleep course is an 18-day program that takes less than 10 minutes per day to complete

New Study Finds Headspace’s Self-Guided Sleep Program Improves Symptoms of Insomnia

Kumar Ramu, Senior Vice President & Managing Director, QPS India.

QPS India Successfully Completes Week-Long US FDA Regulatory Inspection

PR Newswire associated0

PureHealth Reports USD 137.6 Million Net Profit and USD 308.5 Million EBITDA for First Quarter 2025

Alimentiv and Dova Health Intelligence (Previously Satisfai Health Inc.) Launch an AI Solution for Scoring of Ulcerative Colitis (UC) at DDW 2025 in San Diego

A recent post-hoc analysis of Lilly’s SURPASS-3 trial unravels the impact of tirzepatide treatment on muscle volume and fat infiltration in individuals with Type 2 Diabetes

Latest Data from SURPASS-3 Trial Gleans Insight Into the Association of Tirzepatide Treatment with Changes in Muscle Composition in Type 2 Diabetes